148 related articles for article (PubMed ID: 37185613)
1. Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literature.
Robin M; Gras L; Koster L; Saccardi R; Finke J; Forcade E; Rovira M; Kobbe G; Reményi P; Apperley J; Smaranda A; Bay JO; Casper J; de Wreede LC; Giebel S; Grillo G; Heras I; Potter V; Tischer J; Trociukas I; Nachbaur D; Drozd-Sokolowska J; Raj K; Gurnari C; Yakoub-Agha I; Onida F; Scheid C; McLornan D
Bone Marrow Transplant; 2023 Aug; 58(8):942-945. PubMed ID: 37185613
[No Abstract] [Full Text] [Related]
2. Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT.
Robin M; Gras L; Koster L; Gagelmann N; van Gorkom G; Ederr M; Itälä-Remes M; Zuckerman T; Beguin Y; Schaap N; Drozd-Sokolowska J; Raj K; Hayden PJ; de Wreede LC; Battipaglia G; Polverelli N; Czerw T; Hernandez Boluda JC; Kröger N; Yakoub-Agha I; McLornan DP
Br J Haematol; 2024 Feb; 204(2):715-718. PubMed ID: 38014808
[No Abstract] [Full Text] [Related]
3. Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT.
McLornan DP; Gras L; Martin I; Sirait T; Schroeder T; Blau IW; Kuball J; Byrne J; Collin M; Stadler M; Desmier D; Salmenniemi U; Jindra P; Mikhailova N; Lenhoff S; Rifón J; Robin M; Rovira M; Veelken H; Sadowska-Klasa A; Zecca M; Hayden PJ; Czerw T; Hernández-Boluda JC; Yakoub-Agha I
Br J Haematol; 2022 Jul; 198(1):209-213. PubMed ID: 35482558
[No Abstract] [Full Text] [Related]
4. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA-mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT.
Wieczorek M; Labopin M; Castagna L; Brissot E; Socié G; Raiola AM; Angelucci E; Rodríguez AB; Yakoub-Agha I; Aljurf M; Crawley C; Mear JB; Musso M; Fanin R; Avenoso D; Turlure P; Tecchio C; Sanz J; Ciceri F; Nagler A; Mohty M
Am J Hematol; 2023 Feb; 98(2):E41-E44. PubMed ID: 36398703
[No Abstract] [Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Drozd-Sokolowska J; Gras L; Zinger N; Zahrani MA; Passweg J; Byrne J; Ho A; Huang XJ; Kröger N; Mayer J; Russo D; De Becker A; Tbakhi A; Stamatoullas A; Valerius T; Hayden P; McLornan DP; Onida F; Scheid C; Robin M; Yakoub-Agha I
Bone Marrow Transplant; 2023 Feb; 58(2):222-225. PubMed ID: 36402922
[No Abstract] [Full Text] [Related]
7. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT.
Gurnari C; Robin M; Godley LA; Drozd-Sokołowska J; Włodarski MW; Raj K; Onida F; Worel N; Ciceri F; Carbacioglu S; Kenyon M; Aljurf M; Bonfim C; Makishima H; Niemeyer C; Fenaux P; Zebisch A; Hamad N; Chalandon Y; Hellström-Lindberg E; Voso MT; Mecucci C; Duarte FB; Sebert M; Sicre de Fontbrune F; Soulier J; Shimamura A; Lindsley RC; Maciejewski JP; Calado RT; Yakoub-Agha I; McLornan DP
Lancet Haematol; 2023 Dec; 10(12):e994-e1005. PubMed ID: 37898151
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
Albert MH; Slatter MA; Gennery AR; Güngör T; Bakunina K; Markovitch B; Hazelaar S; Sirait T; Courteille V; Aiuti A; Aleinikova OV; Balashov D; Bernardo ME; Bodova I; Bruno B; Cavazzana M; Chiesa R; Fischer A; Hauck F; Ifversen M; Kałwak K; Klein C; Kulagin A; Kupesiz A; Kuskonmaz B; Lindemans CA; Locatelli F; Lum SH; Maschan A; Meisel R; Moshous D; Porta F; Sauer MG; Sedlacek P; Schulz A; Suarez F; Vallée TC; Winiarski JH; Zecca M; Neven B; Veys P; Lankester AC
Blood; 2022 Mar; 139(13):2066-2079. PubMed ID: 35100336
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
[TBL] [Abstract][Full Text] [Related]
10. Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT.
Nabergoj M; Mauff K; Robin M; Kröger N; Angelucci E; Poiré X; Passweg J; Radujkovic A; Platzbecker U; Robinson S; Rambaldi A; Petersen SL; Stölzel F; Stelljes M; Ciceri F; Mayer J; Ladetto M; de Wreede LC; Koster L; Hayden PJ; Czerw T; Hernández-Boluda JC; McLornan D; Chalandon Y; Yakoub-Agha I
Bone Marrow Transplant; 2021 Aug; 56(8):1944-1952. PubMed ID: 33824436
[TBL] [Abstract][Full Text] [Related]
11. Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Battipaglia G; Mauff K; Wendel L; Angelucci E; Mohty M; Arcese W; Santarone S; Rubio MT; Kroger N; Fox ML; Blaise D; Iori AP; Fanin R; Chalandon Y; Pioltelli P; Marotta G; Chiusolo P; Sever M; Solano C; Contentin N; de Wreede LC; Czerw T; Hernandez-Boluda JC; Hayden P; McLornan D; Yakoub-Agha I
Bone Marrow Transplant; 2021 Jul; 56(7):1593-1602. PubMed ID: 33526919
[TBL] [Abstract][Full Text] [Related]
12. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
Ringdén O; Labopin M; Schmid C; Sadeghi B; Polge E; Tischer J; Ganser A; Michallet M; Kanz L; Schwerdtfeger R; Nagler A; Mohty M;
Br J Haematol; 2017 Feb; 176(3):431-439. PubMed ID: 27879990
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
Heidenreich S; Ziagkos D; de Wreede LC; van Biezen A; Finke J; Platzbecker U; Niederwieser D; Einsele H; Bethge W; Schleuning M; Beelen DW; Tischer J; Nagler A; Glass B; Maertens J; Yáñez L; Beguin Y; Sill H; Scheid C; Stelljes M; Ganser A; Zachée P; Selleslag D; de Witte T; Robin M; Kröger N
Biol Blood Marrow Transplant; 2017 Jan; 23(1):44-52. PubMed ID: 27720995
[TBL] [Abstract][Full Text] [Related]
14. Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party.
Robin M; Ruggeri A; Labopin M; Niederwieser D; Tabrizi R; Sanz G; Bourhis JH; van Biezen A; Koenecke C; Blaise D; Tischer J; Craddock C; Maillard N; Mohty M; Russel N; Schetelig J; Finke J; Gluckman E; de Witte TM; Rocha V; Kroger N
Biol Blood Marrow Transplant; 2015 Mar; 21(3):489-95. PubMed ID: 25529382
[TBL] [Abstract][Full Text] [Related]
15. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
16. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
17. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
[TBL] [Abstract][Full Text] [Related]
18. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients.
Lamby P; Wolff D; Mielke S; Grigoleit GU; Ljungman P; Hilgendorf I; Holler E; Holler B; Weber D; Herr W; Schiltz D; Klein S; Graf S; Bjornhagen-Safwenberg V; Dolderer J; Prantl L
Ann Hematol; 2019 Aug; 98(8):1867-1875. PubMed ID: 30993415
[TBL] [Abstract][Full Text] [Related]
20. Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single-center retrospective study.
Huang J; Huang F; Fan Z; Xu N; Xuan L; Liu H; Shi P; Jiang L; Zhang Y; Sun J; Liu Q
Cancer Med; 2020 Sep; 9(17):6244-6255. PubMed ID: 32686915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
